Lupin Limited announced the launch of its Flucytosine capsules USP, 250 mg and 500 mg having received an approval from United States Food and Drug Administration (FDA) earlier. Novel’s, Flucytosine Capsules USP, 250 mg and 500 mg are AB rated generic equivalent of Valeant Pharmaceuticals International inc’s ANCOBON Capsules, 250 mg and 500 mg. Flucytosine Capsules USP, 250 mg and 500 mg are indicated for the treatment of serious infections caused by susceptible strains of Candid and/or Cryptococcus.